LSV Asset Management Decreases Position in United Therapeutics Co. (NASDAQ:UTHR)

LSV Asset Management reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 377,368 shares of the biotechnology company's stock after selling 5,700 shares during the quarter. LSV Asset Management owned 0.80% of United Therapeutics worth $82,979,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Summit Global Investments raised its position in United Therapeutics by 80.5% in the 4th quarter. Summit Global Investments now owns 27,112 shares of the biotechnology company's stock valued at $5,962,000 after buying an additional 12,095 shares during the last quarter. Los Angeles Capital Management LLC lifted its position in shares of United Therapeutics by 43.2% during the fourth quarter. Los Angeles Capital Management LLC now owns 73,405 shares of the biotechnology company's stock valued at $16,141,000 after purchasing an additional 22,155 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in United Therapeutics by 3.1% during the fourth quarter. Fisher Asset Management LLC now owns 3,731 shares of the biotechnology company's stock worth $820,000 after purchasing an additional 112 shares during the last quarter. First Trust Direct Indexing L.P. increased its stake in United Therapeutics by 14.0% in the 4th quarter. First Trust Direct Indexing L.P. now owns 1,527 shares of the biotechnology company's stock valued at $336,000 after buying an additional 187 shares during the last quarter. Finally, New York Life Investment Management LLC lifted its position in shares of United Therapeutics by 4.4% during the 4th quarter. New York Life Investment Management LLC now owns 5,644 shares of the biotechnology company's stock worth $1,241,000 after buying an additional 238 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the transaction, the executive vice president now owns 36,599 shares of the company's stock, valued at approximately $7,880,130.69. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other United Therapeutics news, Director Christopher Patusky sold 1,680 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the sale, the director now owns 4 shares in the company, valued at approximately $896. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 6,000 shares of the company's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the transaction, the executive vice president now owns 36,599 shares of the company's stock, valued at approximately $7,880,130.69. The disclosure for this sale can be found here. Insiders sold a total of 141,790 shares of company stock worth $33,572,685 over the last three months. 12.50% of the stock is owned by insiders.

Analyst Ratings Changes

UTHR has been the subject of a number of research analyst reports. Leerink Partnrs reaffirmed an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, April 11th. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an "overweight" rating in a research report on Thursday, March 7th. HC Wainwright restated a "buy" rating and set a $300.00 price target on shares of United Therapeutics in a research note on Thursday. Finally, The Goldman Sachs Group upped their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a "neutral" rating in a research note on Friday. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $308.78.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $4.27 during mid-day trading on Friday, hitting $262.40. The company had a trading volume of 779,523 shares, compared to its average volume of 541,180. United Therapeutics Co. has a 1 year low of $204.44 and a 1 year high of $262.51. The stock's 50-day moving average price is $236.86 and its 200-day moving average price is $229.35. The company has a current ratio of 3.77, a quick ratio of 4.28 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $11.64 billion, a price-to-earnings ratio of 12.41 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analysts' expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business's revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the prior year, the company posted $4.86 EPS. On average, sell-side analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.